After releasing positive clinical data, ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is making a run for the top in the market this morning. The data came from the company’s Phase 2 CLARITY study, assessing pimavanserin as an option for patients with MDD. With the positive data in mind, excited investors are pushing the stock upward. Today, we’ll … Read more
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company announced that it has received an FDA approval. Of course, the news excited investors, sending the stock on a run for the top. Today, we’ll talk about: The FDA approval; what we’re seeing … Read more
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is having a great start to the trading session this morning after reporting its financial results for the first quarter of 2018. Of course, the report was positive, exciting investors. Today, we’ll talk about: What we saw from the earnings report; what we’re seeing from ACAD as a result; and … Read more
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is having an overwhelmingly strong start to the trading session this morning after announcing poster presentation sof clinical data surrounding Parkinson’s disease that have been presented at the American Academy of Neurology (AAN) Annual Meeting in Los Angeles. ACAD Heads For The Top On Data Presentations As mentioned above, ACADIA … Read more
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is having a strong start to the trading session this morning after rumors broke surrounding the company. The rumors led to excitement which sent the stock toward the sky, prompting our partners at Trade Ideas to alert us to the gains. At the moment (10:30), ACAD is trading at $29.49 … Read more
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Acadia Pharmaceuticals wasn’t off to the best of days in today’s trading session. When the market opened, the stock was trading well into the red. While it made a push for the green, when it broke through the breakeven point, the stock quickly took a dive. Nonetheless, minutes ago, the … Read more
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) ACADIA Pharmaceuticals was off to a relatively normal day in the market today. At the open, the stock was trading slightly in the green. From there, it found it’s way to the red, then saw more movement in both directions, keeping it right around the breakeven point. However, the stock … Read more
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) ACADIA Pharmaceuticals was off to what seemed to be a relatively normal day in the market today. When the opening bell rang, the stock was trading slightly in the green. From there, we saw slow, yet steady gains. That is, until minutes ago, when the stock started to spike for … Read more
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) ACADIA Pharmaceuticals didn’t have the best of days in the market yesterday. In fact, the stock ended the day at $25.43 per share after falling $0.55 per share, or 2.12%. Nonetheless, the stock is doing exceptionally well in pre-market today. Below, we’ll talk about what we’re seeing from the stock, … Read more
Acadia Pharmaceuticals (NASDAQ:ACAD) On Monday, Acadia Pharmaceuticals announced that it had initiated a phase 2 trial in patients with Alzheimer’s Disease Agitation. Once again ACAD will use its drug Pimavanserin to see if the drug will work in this targeted indication. The company has already received FDA approval for Pimavanserin in Parkinson’s Disease Psychosis. Now … Read more